Measurement of levels of infliximab and anti-infliximab antibodies inrheumatic patients

• Conditions: rheumatic diseases; MedDRA version: 16.1Level: PTClassification code 10072736Term: Rheumatic disorderSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders; Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]

• Registration Number: EUCTR2013-004969-14-FI
• Lead Sponsor: Heidi Mäkinen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01-15
• Last Update Posted: 3 February 2014

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Patients with infliximab therapy
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 150
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50

Exclusion Criteria

None

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified